Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Duchenne Surprise: Sarepta Prices Exondys 51 Below Expectations

Executive Summary

It sparked at least one analyst to question how Sarepta came up with a price for FDA's first approved Duchenne muscular dystrophy treatment.

Advertisement

Related Content

Tech Transfer Roundup: Arrakis Gets Penn IP Toward Small Molecule RNA Therapies
Lucky No. 35? Sarepta And BioMarin Settle Global Patent Disputes
Sponsors May Race For Rare Pediatric Voucher Designations As Deadline Nears
Sarepta's Shadow: BioMarin Mulls Turning The Extraordinary Into A Template
Sarepta's Eteplirsen Approved After Contentious Internal FDA Debate
Woodcock's Consideration of Sarepta Financial Issues Raises Eyebrows
Pediatric Rare Disease Voucher Program Faces Expiration
Priority Review Vouchers Appear To Be Dropping In Price
Sarepta's Eteplirsen Review Delay Emboldens Duchenne Community
Patients Can't Rescue Sarepta's Eteplirsen

Topics

Related Companies

Advertisement
UsernamePublicRestriction

Register

SC097320

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel